Clinical Trial Update: A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

First-in-human dose-escalation and expansion trial of AZD8421 (alone or in combination) in selected advanced solid tumors, including ER+ HER2- advanced breast c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Estrogen Receptor-positive Advanced Breast Cancer
• High-grade Serous Ovarian Cancer

Drugs mentioned

• AZD8421

Snippet

Sponsor: AstraZeneca | Conditions: ER+ HER2- Advanced Breast Cancer, High-grade Serous Ovarian Cancer (HGSOC) | Phase 1, Phase 2 | Status: RECRUITING